DiaSorin S.p.A. (LON: 0GZX)

Market Cap	4.76B
Revenue (ttm)	980.44M
Net Income (ttm)	157.15M
Shares Out	n/a
EPS (ttm)	2.95
PE Ratio	30.30
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	May 20, 2024

Volume	11,150
Average Volume	13,668
Open	101.24
Previous Close	101.65
Day's Range	103.10 - 104.70
52-Week Range	63.15 - 92.85
Beta	0.19
RSI	61.61
Earnings Date	Mar 14, 2025

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,233
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2023, DiaSorin's revenue was 1.15 billion, a decrease of -15.64% compared to the previous year's 1.36 billion. Earnings were 159.85 million, a decrease of -33.65%.

Financial numbers in EUR